Device Trial Radar · NCT06340581
A Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer
Last checked: Nov 19, 2026Latest source record: Aug 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Oct 17, 2024
Primary completion
Feb 27, 2025
Study completion Feb 27, 2025
Sponsor
- Lead sponsor
- AstraZenecaNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- Parexel
- First posted
- Apr 1, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to demonstrate the equivalence of budesonide, glycopyrronium, formoterol (BGF) metered dose inhaler (MDI) hydrofluoroolefin (HFO) with a spacer to BGF MDI hydrofluoroalkane (HFA) with a spacer. The secondary objective is to characterize BGF MDI HFO with and without a spacer.
Conditions
- Healthy
Interventions
Treatment A: BGF MDI HFADrug
Participants will receive 4 oral inhalations of BGF MDI HFA as a single dose with AeroChamber Plus Flow-Vu spacer with charcoal.
Treatment B: BGF MDI HFODrug
Participants will receive 4 oral inhalations of BGF MDI HFO as a single dose with AeroChamber Plus Flow-Vu spacer with charcoal.
Treatment C: BGF MDI HFODrug
Participants will receive 4 oral inhalations of BGF MDI HFO as a single dose without spacer with charcoal.
AeroChamber Plus Flow-Vu SpacerDevice
Participants will receive 4 inhalations of BGF MDI HFA (treatment A) and BGF MDI HFO (Treatment B) as a single dose with AeroChamber Plus Flow-Vu spacer.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area Under the Plasma Concentration-curve from Zero to the Last Quantifiable Concentration (AUClast) of BGF MDITime frame: Day 1 and Day 2 of each treatment period (each treatment period is of 2 days)
- Maximum Observed Concentration (Cmax) of BGF MDITime frame: Day 1 and Day 2 of each treatment period (each treatment period is of 2 days)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.